Related Experiment Video
Updated: May 1, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Navigating early recurrences in post-hepatectomy hepatocellular carcinoma: Preventive strategies and prognostic
Mizelle D'Silva1, Gurudutt Varty1, Shraddha Patkar1
1Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Background:
Early recurrence post-resection for hepatocellular carcinoma (HCC) occur within one year of surgery. They are "true" recurrences. Our aim is to identify factors associated with early recurrence and explore potential strategies to improve long-term oncological outcomes.
Methods:
Patients undergoing liver resection for HCC during the period from July 2011 to June 2023 at Tata Memorial Centre, Mumbai were included in the study. Survival was analyzed based on recurrence timing and treatment modalities used.
Results:
Recurrences were noted in 166/336(49.4%) patients. Patients were divided into the early recurrence (ER) (n = 79, 47.6%), late recurrence (LR) (n = 60, 36.1%) and extrahepatic recurrence (EHD) groups (n = 27, 16.3%). There was a significant survival difference between ER, LR and EHD (0.001; 16.8 vs 82.1 vs 44.8 months). On multivariable analysis factors such as satellite tumors (HR 2.164; 95% CI 1.093-4.285; p = 0.027), LVE (HR 1.852; 95% CI 1.013-3.386; p = 0.045) and BCLC B and C stage (HR 1.644; 95% CI 1.163-2.325; p = 0.005) were significantly associated with ER.
Conclusion:
Surgery for HCC is fraught with a high recurrence rate with almost half of the recurrences occurring within one year which are mainly local and are associated with lymphovascular emboli, poorer differentiation, satellite nodules and higher BCLC stage.
